Characteristiks of patients with cystic fibrosis of the Central Federal District of the Russian Federation

The aim of this investigation was to analyse the register of cystic fibrosis (CF) patients of Central Federal District (CFD) of Russian Federation (RF) in 2017. The register of CF patients includes data on 3096 people from 81 regions-entities of RF. CF patients in CFD represent 30% of total amount of patients included in the register. The full data presents 9 regions. The data of the rest 9 regions is presented partially. There is a list of genetically, clinical and microbiological peculiarities in comparison with RF in general and, at the same time, with other districts of CFD. The difference between adult patients and average age of patients by areas of received treatment, laboratory and instrumental indicators. There are obvious differences in infection indicators of the same age groups, there is difference in provided therapy. The analysis of the register data will enable to optimize aid to CF patients in CFD, to take over the experience of regions with the best indicators and criteria of the progress of the disease.

cystic fibrosis, CFTR gene, register, Central Federal District, pseudomonas infection, MRSA, external respiration function

1. Kapranov N.I., Kashirskaja N.Ju. Mukoviscidoz. [Cystic Fibrosis] M.: ID «Medpraktika-M»; 2014.672p (In Russ.)

2. Kelly J. Environmental scan of cystic fibrosis research worldwide. J Cyst Fibros. 2017;16(3):367–370. doi: 10.1016/j.jcf.2016.11.002

3. Cfww.org [Internet]. Cystic Fibrosis Worldwide (CFW). Available from: https://www.cfww.org/. Accessed 12.06.2019

4. MacKenzie T., Gifford A.H., Sabadosa K.A. et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161(4):233–241. doi: 10.7326/M13-0636

5. Sherman V.D., Kondrat’eva E.I.,Voronkova A.Ju. et al. Vlijanie neonatal’nogo skrininga na techenie mukoviscidoza na primere grupp pacientov Moskovskogo regiona. [The effect of neonatal screening on the course of cystic fibrosis by the example of patient groups in the Moscow region.] Medicinskij sovet [Medical Coucil]. 2017; 18: 124–128. (In Russ.)

6. Krasovskij S.A., Kashirskaja N.Ju., Amelina E.L. et al. Registr bol’nyh mukoviscidozom v Rossijskoj Federacii. 2012 god. [Register of cystic fibrosis patients in the Russian Federation. year 2012] Pul’monologija [Pulmonology]. 2015; Prilozhenie [Supplement]: 1–58 (In Russ.)

7. Krasovskij S.A., Amelina E.L., Gorinova Ju.V. et al. Dinamika nekotoryh pokazatelej zdorov’ja vzroslyh bol’nyh mukoviscidozom, nabljudaemyh v NII pul’monologii, za 2003-2018 gg. [Dynamics of some health indicators of adult patients with cystic fibrosis observed at the Research Institute of Pulmonology, 2003-2018.] Klinicheskaja praktika [Clinical practice]. 2018;9(4):26–27 doi: 10.17816/clinpract9425–32 (In Russ.)

8. Voronkova A.Ju., Amelina E.L., Kashirskaja N.Yu. et al. Registr bol’nyh mukoviscidozom v Rossijskoj Federacii. 2017 god. [Register of cystic fibrosis patients in the Russian Federation. 2017 year.] M.: ID «Medpraktika-M», 2019, 68p. (In Russ.)

9. Krasovskij S.A., Amelina E.L., Chernjak A.V. et al. Rol’ registra moskovskogo regiona v vedenii bol’nyh mukoviscidozom. [The role of the register of the Moscow region in the management of patients with cystic fibrosis.] Pul’monologija [Pulmonology]. 2013;(2):27–32. https://doi.org/10.18093/0869-0189-2013-0-2-27-32 (In Russ.)

10. Krasovskij S.A., Chernjak A.V., Amelina E.L. ey al. Dinamika vyzhivaemosti bol’nyh mukoviscidozom v Moskve i Moskovskoj oblasti za periody 1992–2001 i 2002–2011 gg. [The dynamics of survival of patients with cystic fibrosis in Moscow and the Moscow region for the periods 1992–2001 and 2002–2011] Pul’monologija [Pulmonology]. 2012; 3: 79–86 (In Russ.)

11. Quon B.S., Rowe S.M. New and emerging targeted therapies for cystic fibrosis. BMJ. 2016;352:i859. doi: 10.1136/bmj.i859.

12. https://www.ecfs.eu/ecfspr. Accessed 12.06.2019).

13. Sherman V.D., Kashirskaja N.Ju., Kondrat’eva E.I. et al. Mukoviscidoz: opredelenie, diagnosticheskie kriterii, terapija, razdel «Diagnostika mukoviscidoza» [Cystic Fibrosis: Definition, Diagnostic criteria, Therapy. Section «Diagnostics of Cystic Fibrosis”]. Pediatrija [Pediatrics]. 2017; 96 (2): 90–99 (In Russ.)

14. Polgar G., Promadhat V. Pulmonary function testing in children: Techniques and standards. Philadelphia: W.B.Saunders Co; 1971.

15. Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur.Respir. J. 1993; 6 (Suppl. 16): 5–40

16. Sinaasappel M., Stern M., Littlewood J. et al. Nutrition in patients with cystic fibrosis: a European Consensus. J. Cyst.Fibros. 2002; 1 (2): 51–75.

17. Castellani C., Duff A.J.A., Bell S.C. et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 Mar; 17(2): 153–178. doi: 10.1016/j.jcf.2018.02.006

18. WHO.Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization;1995.

19. Petrova N.V., Kondrat’eva E.I., Krasovskij S.A. et al. Proekt nacional’nogo konsensusa «Mukoviscidoz: opredelenie, diagnosticheskie kriterii, terapija». Razdel «Genetika mukoviscidoza. Molekuljarno-geneticheskaja diagnostika pri mukoviscidoze» [Draft national consensus «Cystic fibrosis: definition, diagnostic criteria, therapy». Section «Genetics of cystic fibrosis. Molecular genetic diagnosis in cystic fibrosis]. Medicinskaja genetika [Medical Genetics] 2016;15(11):29–45 (In Russ.)

20. Lee T.W.R., Brownlee L.G., Conway S.P. et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa in cystic fibrosis patients. J. Cyst.Fibros. 2003; 2(1): 29–34.

21. Proesmans M., Balinska-Miskiewicz W., Dupont L. et al. Evaluating the «Leeds criteria»for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur.Resp. J. 2006; 27: 937–943.

22. https://www.orkambi.com. Accessed 12.06.2019

23. https://www.symdeko.com. Accessed 12.06.2019

24. Saiman L., Marshall B.C., Mayer-Hamblett N. et al. Azithromycin in patients with cystic fibrosis chronically infected with seudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290: 1749–1756.

25. https://mukoviscidoz.org/doc/konsensus/CF_consensus_2017.pdf : 127–128

26. Krasovsky S., Gorinova Y., Amelina E. Phenotypic manifestations of rare missense mutations 41th European Cystic Fibrosis Conference, Belgrad, Serbia, 6–9 June 2018/ Journal of Cystic Fibrosis. 2018; 17 (Suppl. 3): S47 EPS2.06 (IF 3.858)

27. Marson F.A., Bertuzzo C.S., Ribeiro J.D. Classification of CFTR mutation classes. Lancet Respir Med. 2016 Aug; 4 (8):37–38 doi: 10.1016/S2213-2600(16)30188-6

28. https://mukoviscidoz.org/doc/konsensus/CF_consensus_2017.pdf : 80-81